Chong Kun Dang Pharmaceutical

Quick facts

Marketed products

• Atorvastatin (Lipilou) · Cardiovascular
  Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood.
• Baraclude Tab. 0.5mg
• Candemore Plus Tab · Cardiovascular
  Candemore Plus is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and amlodipine (a calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition.
• Candemore tablet · Cardiovascular
  Candemore is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce vasoconstriction and lower blood pressure.
• Cantabell Tab · Gastroenterology / Urology
  Cantabell is an antispasmodic agent that relaxes smooth muscle in the gastrointestinal and urinary tracts by blocking muscarinic acetylcholine receptors.
• Conversion to Once-daily Tacrolimus
• Cozzar tablet · Cardiovascular
  Cozzar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.
• empagliflozin 10mg
• EsoDuo® Tablet
• Eupasidin-s Tab
• Everolimus Tab. · Oncology
  Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
• Imotun · Other
• Methylprednisolone/prednisolone · Immunology, Rheumatology, Endocrinology
  Methylprednisolone and prednisolone are corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
• Mycophenolate Mofetil Cap./Tab. · Immunology; Transplantation
  Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses.
• Mycophenolate mofetil Tab./Cap. · Immunology; Transplantation
  Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation.
• Mycophenolate mofetil Tablet/Capsule · Immunology; Transplantation
  Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation.
• Myreptic-N Tablet
• Nafamostat Mesilate · Anticoagulation / Hemostasis
  Nafamostat mesilate is a serine protease inhibitor that blocks multiple coagulation and inflammatory proteases to prevent thrombosis and inflammation.
• Sirolimus Tab. · Immunology, Oncology
  Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation.
• SKYRIZI · Immunology/Dermatology
  SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
• TacroBell SR cap. · Immunology
  TacroBell SR is a sustained-release formulation of tacrolimus that suppresses T-cell activation and proliferation by inhibiting calcineurin phosphatase.
• Tacrolimus cap.
• tacrolimus capsules
• Tacrolimus with Methotrexate

Phase 3 pipeline

• Carvedilol IR 25mg, BID · Cardiovascular
  Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
• Carvedilol IR 25mg, QD · Cardiovascular
  Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
• Carvedilol SR 32mg, QD · Cardiovascular
  Carvedilol SR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
• Carvedilol SR 64mg, QD · Cardiovascular
  Carvedilol SR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
• CKD-11101
  CKD-11101 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not yet publicly disclosed.
• CKD-11101(Darbepoetin alfa) · Hematology/Oncology
  Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.
• CKD-314+SOC · Endocrinology / Diabetes
  CKD-314 is a selective PPAR-gamma agonist that enhances insulin sensitivity and glucose metabolism when combined with standard of care.
• CKD-330
  CKD-330 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not publicly disclosed in standard references.
• CKD-331 · Oncology
  CKD-331 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• CKD-342 · Oncology
  CKD-342 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• CKD-351 · Oncology
  CKD-351 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• CKD-352 · Oncology
  CKD-352 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.
• CKD-390
  CKD-390 is a small molecule inhibitor targeting a specific cellular pathway involved in inflammatory or metabolic disease.
• CKD-701 · Oncology
  CKD-701 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• CKD-825 · Oncology
  CKD-825 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• CKD-828 · Oncology
  CKD-828 is a dual VEGFR2/FGFR1 tyrosine kinase inhibitor that blocks angiogenesis and fibroblast growth factor signaling to inhibit tumor growth.
• CKD-828(placebo)
  CKD-828 is a placebo control used in clinical trials and has no active pharmacological mechanism.
• CKD-843 dose#1 · Oncology
  CKD-843 is a selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-dependent signaling in hormone-sensitive cancers.
• CKD-843 dose#2 · Metabolic/Endocrinology
  CKD-843 is a selective PPAR-gamma agonist that enhances insulin sensitivity and reduces inflammation.
• D012, placebo of D064, placebo of D701
  D012 is a placebo control formulation with no active pharmacological mechanism.
• D013 · Diabetes
  D013 is a small molecule that targets the SGLT2 receptor.
• D013, D326, D337
  D013, D326, and D337 are investigational drugs with unknown mechanisms of action.
• D013(placebo)
  D013 is a placebo control with no active pharmacological mechanism.
• D013, placebo of D326, placebo of D337
  D013 is a placebo control formulation with no active pharmacological mechanism.
• D064 and D702, QD
  D064 and D702 are a fixed-dose combination targeting dual pathways in metabolic or inflammatory disease, though the specific molecular targets are not publicly disclosed.
• D064 and Placebo of D702, QD
  Unfortunately, no information is available on the mechanism of action of D064.
• D064, D701, placebo of D012
  This drug is a small molecule.
• D064, D702, placebo of D660
  This drug is a small molecule.
• D086 · Cardiovascular
  D086 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism.
• D326 · Diabetes
  D326 is a small molecule drug that targets the SGLT2 receptor.
• D326(placebo)
  D326 is a placebo control with no active pharmacological mechanism.
• D337
  D337 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.
• D337(placebo)
  D337 is a placebo control with no active pharmacological mechanism.
• D377
  D377 is an investigational therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical.
• D660, placebo of D064, placebo of D702
  D660 is a placebo control formulation with no active pharmacological mechanism.
• D723
  D723 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.
• D745 formulation I
  D745 formulation I is a small molecule that targets the molecular target.
• D745 formulation II
  D745 formulation II is a drug that targets the molecular target to exert its therapeutic effect.
• D930
  D930 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.
• Isotonic 0.3% Sodium Hyaluronate · Ophthalmology
  Sodium hyaluronate is a viscoelastic substance that lubricates and protects ocular surfaces by mimicking natural tear film components.

Phase 2 pipeline

• CKD-498 dose#1
• CKD-498 dose#2 · Diabetes
  CKD-498 dose#2 is a small molecule that targets the SGLT2 receptor.
• CKD-498 dose#3 · Diabetes
  CKD-498 is a small molecule that targets the SGLT2 receptor.
• CKD-506
• S-amlodipine
• S-Amlodipine, Telmisartan

Phase 1 pipeline

• amlodiopine · Other
• Atrovastatin and Ezetimibe combination therapy · Cardiovascular
  Inhibits HMG-CoA reductase and inhibits cholesterol absorption
• Chong Kun Dang Tamsulosin HCl Tab.
• Chong Kun Dang Tofacitinib Tablet
• Cialis Tab. 5mg
• CKD-320, D012
• CKD-330 1 Tab. and D085 1 Tab.
• CKD-330, D090
• CKD-330 Tab. and D086 Tab.
• CKD-330 Tab. and D090 Tab.
• CKD-331, D337
• CKD-333 1 Tab
• CKD-333, formula I
• CKD-333, formula II
• CKD-333 formulation I
• CKD-333 formulation II
• CKD-333 Tab.
• CKD-337
• CKD-341
• CKD-341, D956
• CKD-341, D958
• CKD-344
• CKD-348
• CKD-348 F1
• CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
• CKD-348 F2
• CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
• CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
• CKD-349
• CKD-349 F1 Tab.
• CKD-349 F2 Tab.
• CKD-357
• CKD-370
• CKD-371
• CKD-375
• CKD-378, QD, PO
• CKD-378, QD, PO Drug: D745, D150, QD, PO
• CKD-379
• CKD-379 I
• CKD-379 II

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chong Kun Dang Pharmaceutical portfolio CI brief
• Chong Kun Dang Pharmaceutical pipeline updates RSS